LB-102

New York, July 22, 2026 LB Pharmaceuticals announced that it now expects to report topline results from the pivotal...

New York, USA | March 27, 2026 LB Pharmaceuticals announced new findings from its Phase 2 NOVA-1 clinical trial,...

NEW YORK, November 6, 2025 — LB Pharmaceuticals Inc. (NASDAQ: LBRX), a clinical-stage biopharmaceutical company focused on developing therapies...